COVID-19: consider cytokine storm syndromes and immunosuppression. Mehta, P.; McAuley, D. F.; Brown, M.; Sanchez, E.; Tattersall, R. S.; and Manson, J. J. The Lancet, 395(10229):1033–1034, March, 2020.
COVID-19: consider cytokine storm syndromes and immunosuppression [link]Paper  doi  abstract   bibtex   

1-liner: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19.

 

Summary

Article type – correspondence letter

Main takeaways:

  • Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, “characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α”
  • Elevated ferritin and IL-6, which may suggest “hyperinflammation,” were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan
  • Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation

 

@article{mehta_covid-19_2020,
	title = {{COVID}-19: consider cytokine storm syndromes and immunosuppression},
	volume = {395},
	issn = {0140-6736, 1474-547X},
	shorttitle = {{COVID}-19},
	url = {https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30628-0/abstract},
	doi = {10.1016/S0140-6736(20)30628-0},
	abstract = {<p><u>1-liner</u>: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19.</p>
<p>\&nbsp;</p>
<p><u>Summary</u></p>
<p>Article type \&ndash; correspondence letter</p>
<p>Main takeaways:</p>
<ul>
<li>Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, \&ldquo;characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-\&gamma; inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-\&alpha;, and tumour necrosis factor-\&alpha;\&rdquo;</li>
<li> Elevated ferritin and IL-6, which may suggest \&ldquo;hyperinflammation,\&rdquo; were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan</li>
<li> Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation</li>
</ul>
<p>\&nbsp;</p>},
	language = {English},
	number = {10229},
	urldate = {2020-04-25},
	journal = {The Lancet},
	author = {Mehta, Puja and McAuley, Daniel F. and Brown, Michael and Sanchez, Emilie and Tattersall, Rachel S. and Manson, Jessica J.},
	month = mar,
	year = {2020},
	pmid = {32192578},
	keywords = {Shradha Kulkarni},
	pages = {1033--1034},
	annote = {1-liner: This correspondence letter published in The Lancet recommends identifying and treating hyperinflammation, such as secondary HLH, in severe COVID-19. 
 
Summary
Article type – correspondence letter
Main takeaways:
-        Severe COVID-19 disease appears to be associated with a cytokine profile resembling secondary HLH, “characterized by increased interleukin (IL)-2, IL-7, granulocyte-colony stimulating factor, interferon-γ inducible protein 10, monocyte chemo-attractant protein 1, macrophage inflammatory protein 1-α, and tumour necrosis factor-α”
-         Elevated ferritin and IL-6, which may suggest “hyperinflammation,” were found to be predictors of fatality from a retrospective study of 150 COVID-19 cases in Wuhan
-        Immunosuppressive agents such as glucocorticoids, IVIG, tocilizumab, anakinra, and JAK inhibitors could be considered for treatment in patients with evidence of hyperinflammation
 },
	file = {Snapshot:C\:\\Users\\mdwan\\Zotero\\storage\\SQE4P4Q2\\Mehta et al. - 2020 - COVID-19 consider cytokine storm syndromes and im.html:text/html}
}
Downloads: 0